Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Encover is a liquid enteral nutrition product developed and marketed by JW Jungwoo Pharmaceutical (a subsidiary of JW Pharmaceutical). It is a specialized nutritional formula designed for patients who are unable to maintain adequate oral intake or who have impaired digestion or absorption. Encover provides a balanced profile of essential macronutrients, including proteins (typically casein and soy protein), carbohydrates (maltodextrin), and fats, along with a comprehensive range of vitamins and minerals. It is particularly indicated for the nutritional management of patients with inflammatory bowel diseases such as Crohn's disease, as well as for post-operative recovery and patients requiring tube feeding. In the South Korean market, it is often regulated as a prescription (ethical) drug due to its specific medical indications.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Encover.